



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Anemia	Current	Reference Range	Previous
Ferritin (ng/mL)	199	30~400	174 (04/13/2019)
Iron (ug/dL)	109	59~158	164 H (04/13/2019)
UIBC (µg/dL)	113	112~347	191 (04/13/2019)
TIBC (µg/dL)	222	171~505	355 (04/13/2019)
Transferrin (mg/dL)	198 L	203~362	156 L (04/13/2019)
Transferrin Saturation (%)	49	15~50	46 (04/13/2019)

Nutrition	Current	Reference Range	Previous
Folate (ng/mL)	>20.0	≥4.6	>20.0 (04/13/2019)
Vitamin D, 25-OH* (ng/mL)	15.0 L	30.0~108.0	19.0 L (04/13/2019)
Vitamin B12 (pg/mL)	<150 L	232~1245	<150 L (04/13/2019)

Comments

Likely vitamin D deficiency. Consider increasing vitamin D intake (e.g., adequate sun exposure and diet supplementation).; Associated with anemia, malnutrition, and malabsorption. Treat underlying cause.



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Lipids	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	Cholesterol, Total (mg/dL)	150			≤199	200~240	≥241	130 04/13/2019
	LDL Calculation (mg/dL)		124		≤99	100~129	≥130	103 04/13/2019
	HDL Direct (mg/dL)			20	≥56	35~55	≤34	20 04/13/2019
	Triglyceride (mg/dL)	30			≤149	150~200	≥201	33 04/13/2019

Comments

Follow NCEP: ATP III guidelines. Dietary strategies to consider include adequate intake of monounsaturated fats and omega-3 fatty acids, moderate alcohol intake, reduction of total carbohydrate to less than 50% of calories, emphasis on low glycemic-load foods and reduction of fructose, weight loss and regular exercise.

LDL Direct	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	LDL Direct (mg/dL)	60			≤99	100~129	≥130	50 04/13/2019



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Inflammation	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	Homocysteine (μmol/L)			20	≤9	10~14	≥15	18 04/13/2019
	hs-CRP (mg/L)			10.1	≤0.9	1.0~3.0	≥3.1	19.1 04/13/2019

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Glycemic Control	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	Glucose(Diabetes) (mg/dL)			20	70~100	101~126	≤69 ≥127	11 04/13/2019
	Hemoglobin A1c (%)			11.0	≤5.6	5.7~6.4	≥6.5	12.0 04/13/2019

Comments

HbA1C: Follow ADA guidelines. Consider losing excess weight, eating a healthy diet that is high in fiber and restricted in carbohydrates, and getting regular amounts of exercise. Consider biguanides, meglitinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and insulin.;

Combining GSP results with HbA1c measurements provides a better assessment of long term risk of diabetic complications.;

GSP: Elevated GSP levels suggest recent (approximately past 2 weeks) sustained hyperglycemia.

Insulin Resistance	Current	Reference Range	Previous
Adiponectin* (ug/mL)	1.1		20.0 (04/13/2019)
Ferritin (ng/mL)	199	30~400	174 (04/13/2019)

Adiponectin:

Your BMI is **22 kg/meters-squared**

Body Mass Index (BMI)	Male	Female
kg/meters-squared	ug/mL	ug/mL
<25	4.7 - 49.2	8.5 - 56.1
25-30	3.8 - 35.0	6.1 - 47.2
>30	2.2 - 32.6	4.9 - 42.1

Body Mass Index (BMI) = (weight in Kg) / (height in metres)²

Beta Cell Function	Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
	Insulin (µU/mL)	12.0				2.6~24.9		≤2.5 ≥25.0



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Thyroid	Current	Reference Range	Previous
T3 - Triiodothyronine (ng/mL)	>6.5 H	0.8~2.0	>6.5 H (04/13/2019)
T4 - Thyroxine (µg/dL)	16.3 H	4.5~9.8	17.8 H (04/13/2019)
Free T3 (pg/mL)	10.7 H	2.0~4.4	18.2 H (04/13/2019)
Free T4 (ng/dL)	>7.8 H	0.9~1.7	>7.8 H (04/13/2019)
TSH (µIU/mL)	20.941 H	0.111~4.910	20.328 H (04/13/2019)
Anti-TPO (IU/mL)	12	≤34	16 (04/13/2019)
Reverse T3* (ng/dL)	51 H	7~23	51 H (04/13/2019)
Anti-TG (IU/mL)	<10.0	≤115.0	<10.0 (04/13/2019)

Labnotes

Anti-TG :- Anti-Tg: The testing method used is an electrochemiluminescence immunoassay "ECLIA" performed on cobas e immunoassay analyzers. The measured anti-Tg value can vary depending on the testing procedure used. Anti-Tg values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

CBC w/ differential and Platelets	Current	Reference Range	Previous
WBC (x 10 ³ /μL)	18.00 H	4.23~9.07	16.00 H (04/13/2019)
RBC (x 10 ⁶ /μL)	>8.60 H	4.63~6.08	>8.60 H (04/13/2019)
Hemoglobin (g/dL)	18.0 H	13.7~17.5	20.0 H (04/13/2019)
Hematocrit (%)	20.0 L	40.1~51.0	11.0LC (04/13/2019)
MCV (fL)	18.0 L	83.5~99.5	10.0 L (04/13/2019)
MCH (pg)	19.0 L	25.7~32.2	17.0 L (04/13/2019)
MCHC (g/dL)	18.0 L	32.3~36.5	12.0 L (04/13/2019)
RDW - SD (fL)	16.0 L	35.1~43.9	10.0 L (04/13/2019)
RDW - CV (%)	16.0 H	11.6~14.4	15.0 H (04/13/2019)
Platelet Count (x 10 ³ /μL)	14.0LC	129.0~326.0	19.0LC (04/13/2019)
Neutrophil (%)	10.0 L	34.0~67.9	16.0 L (04/13/2019)
Lymphocytes (%)	15.0 L	21.8~53.1	20.0 L (04/13/2019)
Monocytes (%)	12.0	5.3~12.2	17.0 H (04/13/2019)
Eosinophils (%)	11.0 H	0.8~7.0	16.0 H (04/13/2019)
Basophils (%)	14.0 H	0.2~1.2	14.0 H (04/13/2019)
Immature Granulocyte (%)	18.0 H	≤2.1	13.0 H (04/13/2019)
Neutrophil Count (x 10 ³ /μL)	20.00 H	1.78~5.38	17.00 H (04/13/2019)
Lymphocyte Count (x 10 ³ /μL)	12.00 H	1.32~3.57	20.00 H (04/13/2019)
Monocytes Count (x 10 ³ /μL)	12.00 H	0.30~0.90	12.00 H (04/13/2019)
Eosinophil Count (x 10 ³ /μL)	10.00 H	≤0.54	10.00 H (04/13/2019)
Basophil Count (x 10 ³ /μL)	20.00 H	≤0.08	10.00 H (04/13/2019)
Immature Granulocyte Count (x 10 ³ /μL)	12.000 H	≤0.100	15.000 H (04/13/2019)
MPV (Mean Platelet Volume) (fL)	16.0 H	9.4~12.4	14.0 H (04/13/2019)
Nucleated RBC count (x 10 ³ /μL)	18.000 H	≤0.012	15.000 H (04/13/2019)
Nucleated RBC % (/100WBC)	20.0 H	≤0.2	17.0 H (04/13/2019)

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Hepatic Function Panel	Current	Reference Range	Previous
ALT (U/L)	13	≤41	17 (04/13/2019)
AST (U/L)	15	≤40	19 (04/13/2019)
Alkaline Phosphatase (U/L)	250 H	40~129	220 H (04/13/2019)
Bili, Total (mg/dL)	16.5 H	≤1.2	15.8 H (04/13/2019)
Bili, Direct (mg/dL)	>20.0 H	≤0.3	18.7 H (04/13/2019)
Protein, Total (g/dL)	11.7 H	6.2~8.0	15.3 H (04/13/2019)

Renal Function Panel	Current	Reference Range	Previous
Sodium (mmol/L)	<80LC	136~145	<80LC (04/13/2019)
Chloride (mmol/L)	<60 L	98~107	<60 L (04/13/2019)
Potassium (mmol/L)	>10.0HC	3.5~5.1	>10.0HC (04/13/2019)
Carbon Dioxide (mmol/L)	18	18~29	17 L (04/13/2019)
Creatinine (mg/dL)	13.00 H	0.70~1.20	17.20 H (04/13/2019)
eGFR (mL/min/1.73m ²)	5 L	≥60	5 L (05/12/2019)
eGFR(African-American) (mL/min/1.73m ²)	6 L	≥60	4 L (04/13/2019)
BUN (mg/dL)	12	6~20	21 H (04/13/2019)
BUN/Creatinine Ratio	1 L	10~20	1 L (04/13/2019)
Calcium (mg/dL)	12.3 H	8.9~10.6	20.5HC (04/13/2019)
Glucose(Renal) (mg/dL)	16LC	70~100	15LC (04/13/2019)
Phosphate, Inorganic (mg/dL)	11.2 H	2.5~4.5	18.6 H (04/13/2019)
Albumin (g/dL)	4.2	3.5~5.2	4.0 (04/13/2019)

Labnotes

eGFR :- The eGFR is calculated from the Creatinine result and varies by patient gender, age and race. If patient is African-American, the eGFR(African-American) value is applicable.



LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Tumor Markers	Current	Reference Range	Previous
PSA (Total) (ng/mL)	11.68 H	≤4.00	15.26 H (04/13/2019)
Free PSA (ng/mL)	12.00		18.16 (04/13/2019)
Free PSA% (%)	>100.0	≥30.0	>100.0 (04/13/2019)

Labnotes

PSA (Total) :- The testing method used is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc. and performed on the Modular or Cobas system.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

Free PSA :- The testing method used is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc. and performed on the Modular or Cobas system.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.

SAMPLE

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
VIBRANT AMERICA	DEMO	MALE	1996-11-29	1905130043	05-12-2019 09:43

Other Markers	Current	Reference Range	Previous
LDH (U/L)	17 L	135-225	12 L (04/13/2019)
ESR (Erythrocyte Sedimentation Rate) (mm/hour)	17 H	≤15	12 (04/13/2019)
Leptin* (ng/mL)	28.0		33.0 (04/13/2019)

Labnotes

Uric Acid :- N-acetyl-p-benzoquinone imine (metabolite of Acetaminophen) will generate erroneously low results for Uric Acid in samples for patients that have taken toxic doses of acetaminophen.

Leptin:

Your BMI is **22 kg/meters-squared**

Body Mass Index (BMI)	Age	Male	Female
kg/meters-squared	Years	ng/mL	ng/mL
18-25	>18	1.1-13.4	4.7-23.7
25-30	>18	1.8-19.9	8.0-38.9
N/A	5-9.9	1.1-16.8	
N/A	10-13.9	1.4-16.5	
N/A	14-17.9	1.1-24.9	
Body Mass Index (BMI) = (weight in Kg) / (height in metres) ²			